Melissa Hagan

Bio:

Melissa Hagan, PhD, MPH, is Director, US Market Access Strategic Evidence at BeOne Medicines (formerly BeiGene), where she leads market access evidence-generation strategy across the hematology and solid tumor portfolio. In this role, she partners cross-functionally with Account teams, HEOR, Medical Affairs, Biostatistics, and Commercial colleagues to ensure real-world evidence supports payer expectations, launch readiness, and long-term access positioning.

A PhD-trained epidemiologist, Dr. Hagan brings more than 12 years of biopharmaceutical research, health economics and outcomes research, and real-world evidence leadership spanning oncology, cardiovascular disease, neurology, and rare disease. Prior to BeOne, she held senior HEOR and RWE leadership roles at Bristol Myers Squibb and Mitsubishi Tanabe Pharma America, where she led cross-functional teams and directed evidence strategies that informed payer and formulary decision-making.

Dr. Hagan is a frequent presenter and widely published author, with real-world evidence research featured at major scientific conferences and in peer-reviewed journals across oncology, cardiovascular disease, and neurology. She holds a PhD and MPH in Epidemiology from the University of Pittsburgh Graduate School of Public Health.